Singapore, July 25 -- Day 2 of BIO Asia-Taiwan 2025 unfolded with palpable energy and a heightened sense of purpose as stakeholders from academia, industry, and investment converged to unpack the science, strategy, and partnerships driving the region's biotechnology renaissance.
At the TaiNEX1 Innovation Forum, discussions began by exploring how artificial intelligence is revolutionising translational medicine. Delegates were captivated by case studies showcasing how deep learning models are accelerating biomarker identification and streamlining patient stratification for complex diseases. A key highlight came from Professor Min-Hao Lee of Taipei Medical University, who remarked, "AI is no longer a theoretical enhancement-it's a clinical...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.